Abstract Efficacy Side effects References
ChemicalBook > CAS DataBase List > Citalopram hydrobromide

Citalopram hydrobromide

Abstract Efficacy Side effects References
Citalopram hydrobromide Structure
Citalopram hydrobromide
  • CAS No.59729-32-7
  • Chemical Name:Citalopram hydrobromide
  • CBNumber:CB2736240
  • Molecular Formula:C20H22BrFN2O
  • Formula Weight:405.3
  • MOL File:59729-32-7.mol
Citalopram hydrobromide Property
  • Melting point: :182-188°C
  • Flash point: :9℃
  • storage temp.  :-20°C Freezer
  • solubility  :H2O: soluble (sparingly)
  • form  :powder
  • Merck  :14,2318
  • Stability: :Stable. Incompatible with strong oxidizing agents.
  • CAS DataBase Reference :59729-32-7(CAS DataBase Reference)
  • EWG's Food Scores :1
  • FDA UNII :I1E9D14F36
Hazard and Precautionary Statements (GHS)
  • Symbol(GHS)
  • Signal wordDanger
  • Hazard statements H302-H225-H301+H311+H331-H370
  • Precautionary statements P301+P312+P330-P210-P260-P280-P301+P310-P311
Citalopram hydrobromide Price More Price(15)
  • Brand: Sigma-Aldrich
  • Product number: C-057
  • Product name : Citalopram hydrobromide solution
  • Purity: 
  • Packaging: 057-1ml
  • Price: $55
  • Updated: 2020/08/18
  • Buy: Buy
  • Brand: Sigma-Aldrich
  • Product number: 1134233
  • Product name : Citalopram hydrobromide
  • Purity: United States Pharmacopeia (USP) Reference Standard
  • Packaging: 200mg
  • Price: $731
  • Updated: 2020/08/18
  • Buy: Buy
  • Brand: TCI Chemical
  • Product number: C2370
  • Product name : Citalopram Hydrobromide
  • Purity: >98.0%(HPLC)(T)
  • Packaging: 1g
  • Price: $90
  • Updated: 2020/06/24
  • Buy: Buy
  • Brand: TCI Chemical
  • Product number: C2370
  • Product name : Citalopram Hydrobromide
  • Purity: >98.0%(HPLC)(T)
  • Packaging: 5g
  • Price: $310
  • Updated: 2020/06/24
  • Buy: Buy
  • Brand: Cayman Chemical
  • Product number: 14572
  • Product name : Citalopram (hydrobromide)
  • Purity: ≥98%
  • Packaging: 1g
  • Price: $945
  • Updated: 2020/06/24
  • Buy: Buy

Citalopram hydrobromide Chemical Properties,Usage,Production

  • Abstract Citalopram hydrobromide (citalopram HBr) is an orally administered selective serotonin reuptake inhibitor (SSRI) with a chemical structure unrelated to that of other SSRIs or of tricyclic, tetracyclic, or other available antidepressant agents.
    Citalopram HBr occurs as a fine, white to off-white powder. Citalopram HBr is sparingly soluble in water and soluble in ethanol.
    The tablet is available as the brand-name drug Celexa. In Australia, the UK, Germany, Portugal, Poland, and most European countries, it is licensed for depressive episodes and panic disorder with or without agoraphobia. In Spain, it is also used for obsessive-compulsive disorder.
  • Efficacy The advantage of this drug is that it has no effect on cholinergic muscarinic receptors, histamine receptors and α-adrenergic receptors . Because if these receptors are inhibited,  a lot of side effects caused by antidepressants will produce, such as dry mouth, sedation, orthostatic hypotension. Citalopram hydrobromide is effective for not only endogenous depression patients but also non-endogenous depression patients. Its antidepressant effect is usually established after 2-4 weeks . Citalopram hydrobromide does not affect the cardiac conduction system and blood pressure, which is particularly important for elderly patients. In addition, citalopram hydrobromide does not affect the blood, liver and kidney systems. Rare side effects and the most mild sedative properties make it particularly suitable for long-term treatment.It does not lead to weight gaining,and it does not strengthen the role of alcohol.
  • Side effects You should not use this medicine if you are allergic to citalopram or escitalopram (Lexapro), or if you also take pimozide.
    Do not use citalopram if you have used an monoamine oxidase inhibitor (MAOI) in the past 14 days. A dangerous drug interaction could occur. MAOI inhibitors include isocarboxazid, linezolid, methylene blue injection, phenelzine, rasagiline, selegiline, tranylcypromine, and others.
    Side effects are usually small, very mild and transient. The most common adverse reactions are: nausea, increased sweating, salivation reduction, headaches and sleep time shortening. They are usually more obvious in the first or second week when treatment begins, and they generally disappear with the improvement of depression. In rare cases ,seizures have been observed. For  patients who suffer bradycardia , bradycardia can make treatment more complicated.
  • References http://www.rxlist.com/celexa-drug.htm
  • Chemical Properties White or almost white, crystalline powder.
  • Originator Celexa,Lundbeck, Forest
  • Uses An inhibitor of serotonin (5-HT) uptake. Used as an antidepressant
  • Uses Antidepressant;5HT uptake inhibitor
  • Uses Anti-depressant/Anti-psychotic
  • Manufacturing Process 5-Carboxy-1-(4-fluorophenyl)-1-(3-dimethylaminopropyl)-1,3- dihydroisobenzofuranwas synthesized by three methods: 1. A solution of 1-(4-fluorophenyl)-1-(3-dimethylaminopropyl)-1,3-dihydroisobenzofuran-5-yl magnesium bromide in dry THF (90 mL) (prepared by ordinary methods from 5-bromo-1-(4-fluorophenyl)-1-(3-
    dimethylaminopropyl)-1,3-dihydro-isobenzofuran (9 g, 0.024 mole) and
    magnesium (0.73 g, 0.03 mole)) was added to dry solid CO2 (50 g). After addition, the mixture was left at room temperature for 16 hours. The volatile materials were removed in vacuo and the residue was taken up in water (100 mL). pH was adjusted to 5.5 by adding HCl (aqueous, 4 N). The aqueous phase was extracted with toluene (100 mL). The toluene was removed in vacuo and the 5-carboxy-1-(4-fluorophenyl)-1-(3-dimethylaminopropyl)-1,3- dihydroisobenzofuran was obtained as oil. Yield 6 g.
    2. To a solution of 5-bromo-1-(4-fluorophenyl)-1-(3-dimethylaminopropyl)- 1,3-dihydroisobenzofuran (9 g, 0.024 mole) in tertbutyl methyl ether (150 mL) was added n-BuLi (1.6 M in hexanes, 40 mL) at -78 to -65°C. The temperature of the solution was allowed to raise to -30°C over a period of 2 hours. The reaction mixture was added to dry solid CO2 (50 g). After addition, the mixture was left at room temperature for 16 hours. The volatile materials were removed in vacuo and the residue was taken up in water (100 mL). pH was adjusted to 5.5 by adding HCl (aqueous, 4 N). The aqueous phase was extracted with toluene (100 mL). The toluene was removed in vacuo and the 5-carboxy-1-(4-fluorophenyl)-1-(3-dimethylaminopropyl)-1,3- dihydroisobenzofuran was obtained as an oil. Yield 7.5 g.
    3. n-BuLi (20 mL, 1.6 M in hexane) was added to a solution of isopropylmagnesium chloride (8.0 mL, 2 M in diethyl ether) in THF (25 mL) at 0°C. The resulting mixture was stirred at 0°C for 1 h, then cooled to -78°C and a solution of 5-bromo-1-(4-fluorophenyl)-1-(3-dimethylaminopropyl)-1,3- dihydro-isobenzofuran (5.0 g, 13.0 mmol) in THF (25 mL) was added. The mixture was allowed to warm to -10°C during 1 h, then cooled again to -78°C and CO2 (5.7 g, 130 mmol) was added. The mixture was allowed to warm to room temperature, and then evaporated. Ion exchange chromatography of the residue (Dowex RTM-50, acidic form) eluting with 1 M NH3 afforded the 5- carboxy-1-(4-fluorophenyl)-1-(3-dimethylaminopropyl)-1,3- dihydroisobenzofuran as a thick oil.
    5-Carboxy-1-(4-fluorophenyl)-1-(3-dimethylaminopropyl)-1,3- dihydroisobenzofuran (5 g, 0.015 mole) and sulfamide (1.65 g, 0.017 mole) were dissolved in sulfolane (15 mL). Thionyl chloride (2.25 g, 0.019 mole) was added at room temperature and the temperature of the reaction mixture was raised to 130°C for 2 hours. The reaction mixture was allowed to cool to 75°C and water (25 mL) was added. The temperature was held at 75°C for 15 min, and then the reaction mixture was cooled to room temperature. pH was ajusted to 9 with ammonium hydroxide and then n-heptane (75 mL) was added. The temperature was raised to 70°C and the hot n-heptane layer was isolated from which the 5-cyano-1-(4-fluorophenyl)-1-(3- dimethylaminopropyl)-1,3-dihydroisobenzofuran (Citalopram, free base) crystallised on cooling. Yield 3.77 g. Purity (HPLC peak area) >97%. The hydrobromide was prepared in conventional manner and crystallized from isopropanol; melting point 148-150°C.
  • brand name Celexa (Forest).
  • Therapeutic Function Antidepressant
  • Hazard A poison.
Citalopram hydrobromide Preparation Products And Raw materials
Raw materials
Preparation Products
  • Supplier:
    Henan Tianfu Chemical Co.,Ltd.
  • Tel:0371-55170693
  • Fax:0371-55170693
  • Email:info@tianfuchem.com
  • Country:CHINA
  • ProdList:22623
  • Advantage:55
  • Supplier:
    career henan chemical co
  • Tel:+86-371-86658258
  • Fax:
  • Email:sales@coreychem.com
  • Country:CHINA
  • ProdList:30032
  • Advantage:58
  • Supplier:
  • Tel:(323) 306-3136
  • Fax:(626) 453-0409
  • Email:orders@qcchemical.com
  • Country:United States
  • ProdList:8406
  • Advantage:58
  • Supplier:
    Xiamen AmoyChem Co., Ltd
  • Tel:+86 592-605 1114
  • Fax:
  • Email:sales@amoychem.com
  • Country:CHINA
  • ProdList:6371
  • Advantage:58
59729-32-7, Citalopram hydrobromideRelated Search:
  • Citalopran HBr
  • 1-(3-(Dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile hydrobromi
  • Citalopram hydrobromide solution
  • Citalopram HBr Salt
  • 1-(3-(Dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile hydrobr
  • Citalopram Hydrobromide (200 mg)
  • 1-(3-DiMethylaMino-propyl)-1-(4-fluoro-phenyl)-1,3-dihydro-isobenzofuran-5- carbonitrile hydrobroMide
  • CitalopraM HBr API
  • 5-Isobenzofurancarbonitrile, 1-[3-(diMethylaMino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-, hydrobroMide
  • Citalopram hydrobromide, 95%, selective serotonin reuptake inhibitor (SSRI)
  • Citalopram Hydrobromide Tablets
  • 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile monohydrobromide
  • 1-(4'-Fluorophenyl)-1-(3-dimethylaminopropyl)-5-phthalancarbonitrilehydrobromide
  • Citalopramehydrobromide
  • Nitalapram, LU-10-171, 1-[3-(Dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dizohydro-5-isobenzofurancarbonitrile Hydrobromide Sal
  • 5-Isobenzofurancarbonitrile, 1-3-(dimethylamino)propyl-1-(4-fluorophenyl)-1,3-dihydro-, monohydrobromide
  • Nitalapram, LU-10-171, 1-[3-(Dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dizohydro-5-isobenzofurancarbonitrile Hydrobromide Salt
  • 5-isobenzofurancarbonitrile,1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3
  • 1-(3-(Dimethylamino)-propyl)-1-(p-fluorophenyl)-5-phthalancarbonitrile, hydrobromide
  • Citalopram-D4Br
  • Citaloplam hydrobromide
  • CitalopraM HydrobroMide, USP
  • Citalopram hydrobromide,1-[3-(Dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancarbonitrile hydrobromide
  • Citalopram Hydrobromide (125 mg)
  • 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-isobenzofuran-5-carbonitrile hydrobromide
  • Citalopram hydrogen bromide
  • 3-[(1RS)-5-Chloro-1-(4-fluorophenyl
  • Citalopram for system suitability CRS
  • Citalopram Hydrobromide &gt
  • Citalopram hydrobromide CRS
  • Bonitrile HBr
  • Lu 10-171 HBr
  • 59729-32-7
  • 9729-33-8
  • C20H21FN2OHBrC20H22BrFN2O
  • C20H21FN2OBrH
  • C20H21FN2OHBr
  • C20H22BrFN2O
  • Pharmaceutical intermdiate
  • Other APIs
  • Serotonin
  • APIs
  • Neurochemicals,Pharmaceuticals
  • Heterocyclic Compounds
  • Intermediates & Fine Chemicals
  • Neurochemicals
  • Pharmaceuticals
  • Citalopram